Scarica l'app Stockscreener
4.25
2.07%
-0.09
Dopo l'orario di chiusura:
4.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.34
Aprire:
$4.32
Volume 24 ore:
4.32M
Relative Volume:
1.31
Capitalizzazione di mercato:
$366.40M
Reddito:
$7.62M
Utile/perdita netta:
$-271.60M
Rapporto P/E:
-1.2137
EPS:
-3.5018
Flusso di cassa netto:
$-271.54M
1 W Prestazione:
-6.90%
1M Prestazione:
-67.48%
6M Prestazione:
-72.47%
1 anno Prestazione:
-68.63%
Intervallo 1D:
$4.10
$4.40
Intervallo di 1 settimana:
$4.10
$4.69
Portata 52W:
$3.95
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
4.25 | 374.16M | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead - Investing.com Canada
EyePoint posts updated presentation showing LUGANO Phase 3 DURAVYU topline results, NDA path to H1 2027 - TradingView
Eye drug cuts injections 42% in EyePoint (EYPT) trial but misses its main goal - Stock Titan
EyePoint Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
EyePoint at Citi summit: wet AMD setback, but path stays open - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - GlobeNewswire Inc.
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - Kalkine
Investment firm discloses double-digit stake in EyePoint (EYPT) - Stock Titan
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - pluang.com
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - Yahoo Finance
EyePoint faces securities fraud probe after tri... - pluang.com
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - GlobeNewswire
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - quiverquant.com
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - marketscreener.com
Four retinal-disease studies are slated for Los Angeles. EyePoint will present them. - Stock Titan
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - Investing.com
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Pharmaceuticals Inc (EYPT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Eyepoint Pharmaceuticals Inc (EYPT) Key Financial Ratios – Valuation, Profitability & More - Value Research
EyePoint faces securities fraud probe after Pha... - pluang.com
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney - GlobeNewswire
EyePoint (EYPT) CFO moves 139K shares into family and annuity trusts - Stock Titan
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70% - The Economic Times
Taxes of EyePoint, Inc. – HAM:PV3B - TradingView
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) - Business Wire
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals - PR Newswire
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Stocktwits
EyePoint's Wet AMD Drug Duravyu Fails Key Late-Stage Trial - Medical Dialogues
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's Why - MarketBeat
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown (NASDAQ:EYPT) - Seeking Alpha
EyePoint: Still A Sell After Phase 3 Crash (NASDAQ:EYPT) - Seeking Alpha
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold" - MarketBeat
These Analysts Slash Their Forecasts On EyePoint - Sahm
EyePoint director Karen L. Zaderej buys $52,258 in stock - Investing.com South Africa
EyePoint director Karen Zaderej reports purchase of 10,600 shares worth $52,258 - Bitget
EyePoint (EYPT) Insider Karen Zaderej Buys 10,600 Shares, Signaling Confidence - GuruFocus
EyePoint Director Karen Zaderej Acquires 10,600 Shares in Open-Market Transaction - Kalkine Media
EyePoint director Karen L. Zaderej buys $52,258 in stock By Investing.com - Investing.com Australia
EyePoint (EYPT) director adds to stake in open‑market buy - Stock Titan
EyePoint IncInterim Phase 3 Data Shows Con - Moomoo
EYPT Maintains Buy Rating by Citigroup -- Price Target Lowered to $17.00 - GuruFocus
EyePoint Inc. (EYPT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):